COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer

Abstract Tumour-stroma ratio (TSR) is a novel potential prognostic factor in cancers and based on the proportions of stroma and tumour area. The prognostic value of TSR in gastric cancer is incompletely known. The aim of this study was to estimate prognostic significance of TSR in gastric adenocarcinoma. A search of PubMed (MEDLINE), Web of Science, EMBASE, Cochrane and Scopus databases was performed. A meta-analysis was conducted on five-year survival in gastric cancer patients using inverse variance random-effects methods. The literature search yielded 5329 potential titles, of which a total of seven studies were eligible. Results of six studies including a total of 1779 patients were pooled in the meta-analysis. Only 23 (1.3%) of the patients received neoadjuvant therapy. All six studies had a cut-off of 50% for the proportion of stroma when dividing the patients into low- and high stroma groups. Low TSR (high amount of stroma) was strongly associated with increased five-year mortality (hazard ratio 2.19, 95% CI 1.69–2.85). In conclusion, TSR is a strong prognostic factor in gastric cancer. It could be used to estimate prognosis of gastric cancer patients not receiving neoadjuvant chemotherapy. Further studies including patients receiving neoadjuvant therapy are recommended.

Download Full-text

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2016.02.026 ◽

2016 ◽

Vol 16 ◽

pp. S67-S73 ◽

Cited By ~ 1

Author(s):

Ali N. Chamseddine ◽

Monica Cabrero ◽

Yue Wei ◽

Irene Ganan-Gomez ◽

Simona Colla ◽

...

Keyword(s):

Prognostic Factor ◽

Myelodysplastic Syndrome ◽

Differential Expression ◽

Therapeutic Target ◽

Chronic Myelomonocytic Leukemia ◽

Potential Prognostic Factor ◽

Myelomonocytic Leukemia

Download Full-text

CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer

Cancer Medicine ◽

10.1002/cam4.478 ◽

2015 ◽

Vol 4 (9) ◽

pp. 1322-1333 ◽

Cited By ~ 49

Author(s):

Kazumichi Yoshida ◽

Hironori Tsujimoto ◽

Kouji Matsumura ◽

Manabu Kinoshita ◽

Risa Takahata ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Therapeutic Target ◽

Adverse Prognostic Factor

Download Full-text

Hypoxia Promotes Metastasis of Gastric Cancer Through ANXA1 Pathway

10.21203/rs.3.rs-1015054/v1 ◽

2021 ◽

Author(s):

Qing-Hua Liu ◽

Lei Xia ◽

Xiao-Yue Wu ◽

Chen-Chen Lu ◽

Jing-Yuan Song ◽

...

Keyword(s):

Gastric Cancer ◽

Cell Migration ◽

Prognostic Factor ◽

Therapeutic Target ◽

Prognostic Markers ◽

Migration And Invasion ◽

Annexin A1 ◽

Node Metastasis ◽

Hif Pathway

Abstract Background: To determinethe involvement of hypoxia inducible factor1α (HIF) pathway inmetastasis of gastric cancer (GC). Method: It was determined that the expression of HIF and annexin A1 (ANXA1) in human GC (n=76),using immunohis to chemistry, as well as,the involvement of HIF pathway in GC cell migration and invasion in vitro. The correlation between HIF/ANXA1 and the prognosis wasalso evaluated.Results: HIF1αwas substantiallyupregulatedin GC tissues, compared to that of non-cancer. HIF1α was positively correlated withlymph node metastasis, but inversely correlated with survival in GC patients. HIF1αwas an independent prognostic factor in GC patients, and the combination of HIF1α and ANXA1 might serve asuseful prognostic markers in GCpatients.Furthermore,HIF-1αseems topromote GC migration and invasion through HIF1α/ANXA1/MMP-2 pathway. Conclusions: Our findings suggestthat HIF-1αmay serve as a promising prognostic biomarkerand therapeutic target for inhibiting GC metastasis.

Download Full-text